Jasper Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for JSPR, updated each market day.
JSPR AI Sentiment
AI predicts Jasper Therapeutics, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Jasper Therapeutics, Inc. Common Stock
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Sector
Exchange
Market Cap
$23,058,180
Cap Tier
Employees
22
Headquarters
REDWOOD CITY, CA
Listed Since
Sept. 27, 2021
JSPR Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
JSPR Volatility
Jasper Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
